MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/pbc.28273

Медицинская библиотека · Pediatric blood & cancer · 2020

Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations.

Jain Richa, Hans Rekha, Totadri Sidharth, Trehan Amita, Sharma Ratti Ram, Menon Prema, Kapoor Rakesh, Saxena Akshay Kumar, Mittal Bhagwant Rai, Bhatia Prateek, Kakkar Nandita, Srinivasan Radhika, Rajwanshi Arvind, Varma Neelam, Samujh Ram, Marwaha Neelam, Bansal Deepak

СтатьяПеревод в очереди

Аннотация

BACKGROUND

The majority of patients in low- and middle-income countries (LMIC) are unable to receive optimal therapy, including autologous stem cell transplant (ASCT) for high-risk neuroblastoma. Management is intensive and multidisciplinary; survival is often poor. We report a single-center outcome of high-risk neuroblastoma, with adaptations optimized for LMIC.

PROCEDURE: The study was retrospective. Patients were treated on the backbone of the high-risk neuroblastoma study-1 of SIOP-Europe (HR-NBL1/SIOPEN) protocol with ASCT. Adaptations incorporated to decrease cost, requirement for inpatient admission, infections, and faster engraftment included (a) optional outpatient administration for rapid-COJEC, (b) two sessions of stem-cell apheresis, (c) storing stem cells at 2-6°C without cryopreservation for up to 7 days, (d) no central lines, (e) no antibacterial/antifungal/antiviral prophylaxis, (f) omitting formal assessment of cardiac/renal/pulmonary functions before ASCT, and (g) administration of pegylated granulocyte colony-stimulating factor on Day +4.

RESULTS

Over 5 years 9 months, 35 patients with high-risk neuroblastoma were treated. Rapid-COJEC was administered over a median duration of 80 days (interquartile range: 77, 83). Conditioning regimen included melphalan (n = 7), oral busulfan-melphalan (Bu/Mel; n = 6), or intravenous Bu/Mel (n = 22). The median viability of stem cells stored for 6 days (n = 28) was 93% (range: 88-99). Two (5.7%) patients had ASCT-related mortality. The 3-year overall and event-free survival was 41% and 39%, respectively. A relapse occurred in 20 (57%) patients. Treatment abandonment was observed in one (3%) patient.

CONCLUSIONS

Administration of therapy in a disciplined time frame along with low-cost adaptations enables to manage high-risk neuroblastoma with low abandonment and an encouraging survival in LMIC. Stem cells can be stored safely without cryopreservation for up to 7 days.

Для цитирования: Jain Richa, Hans Rekha, Totadri Sidharth, Trehan Amita, Sharma Ratti Ram, Menon Prema, Kapoor Rakesh, Saxena Akshay Kumar, Mittal Bhagwant Rai, Bhatia Prateek, Kakkar Nandita, Srinivasan Radhika, Rajwanshi Arvind, Varma Neelam, Samujh Ram, Marwaha Neelam, Bansal Deepak. Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations.. Pediatric blood & cancer. 2020. DOI: 10.1002/pbc.28273.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.